Lexicon Pharmaceuticals, Inc. LXRX

LXRX Company Overview

Lexicon Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines for metabolic, cardiovascular, and neuropathic diseases. The company operates within the biotechnology and specialty pharmaceutical industries and has historically emphasized genetically informed drug discovery using internally developed research platforms. Lexicon’s primary revenue drivers have included collaboration revenues, licensing agreements, milestone payments, and, increasingly, commercial product sales tied to approved therapies. Its core therapeutic focus areas include diabetes, heart failure, obesity-related metabolic disorders, and neuropathic pain.

The company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon became known for its large-scale gene knockout technology platform, which was designed to identify gene functions and therapeutic targets. Over time, the company transitioned from a primarily research-driven biotechnology enterprise toward a commercial-stage pharmaceutical model. A major milestone in its evolution was the development of sotagliflozin, a dual SGLT1/SGLT2 inhibitor commercialized under the brand name INPEFA for certain heart failure indications in the United States. Lexicon’s strategic positioning has centered on leveraging differentiated mechanisms of action and maintaining a focused specialty pipeline in areas with significant unmet medical need.